

BIOCHEMICAL PHARMACOLOGY DISCUSSION GROUP

NEW YORK ACADEMY OF SCIENCES

JOSE R. PEREZ, PhD
Co-Chair, BPDG
Pfizer Global Res & Dev
(860) 441-8806
jose.r.perez@pfizer.com

JUNE SONNENBERG, PhD
Secretary, BPDG
Wyeth Research
(732)274-4239
sonnenj3@wyeth.com

CHARLES A. LUNN, PhD
Program Coordinator, BPDG
Schering-Plough Research Institute
(908)740-3075
charles.lunn@spcorp.com

MARLA WEETALL, PhD
Co-Chair, BPDG
PTC Therapeutics
(908)222-7000 x111
mweetall@ptcbio.com

EXECUTIVE COMMITTEE

Ilidko Antal, PhD
Bristol Myers Squibb

Ahmad Fawzi, PhD
Acucela Inc.

Carolyn Foster, PhD
Boehringer Ingelheim
Pharmaceuticals

Steven Gross, PhD
Cornell University Medical College

John Hambor, PhD
Cognate BioServices

Julia Heinrich, PhD
Wyeth Research

Huiping Jiang, PhD
Boehringer Ingelheim
Pharmaceuticals

Janet Kerr, PhD
Merck Research Laboratories

Kenneth La Montagne, PhD
Johnson & Johnson

Barbara Petrack, PhD
Drew University

Esther Sabban, PhD
New York Medical College

JoAnne Saye, PhD
AstraZeneca

Janet Sredy, PhD
Adservio LLC

Ross Tracey
Pfizer Global Res & Dev

Lawrence Wennogle, PhD
Intra-Cellular Therapies Inc

George Zavoico, PhD
Cantor Fitzgerald

Clinical Studies on the Therapeutic Value of Adult Human Stem Cells

Tuesday, September 25, 2007

8:30 AM – 5:00 PM @ The Lighthouse International Conference Center

Organizers: Keith Haskell, M.A., Pfizer Global R&D and
John Hambor, Ph.D., Cognate Bioservices

Adult stem cells possess properties of self-renewal and pluripotency where they play a role in homeostatic tissue regeneration, as well as the repair of injured or diseased tissue. An accepted modality, adult stem cells have been used either exclusively or in combination with other treatments to achieve significant healthcare benefits for sufferers of multiple conditions. Furthermore, the future application of adult stem cells for treatment therapies, where clinical trials have already indicated significant potential benefit, include Parkinson's Alzheimer's, spinal cord injuries, organ transplantation, blood production, muscle regeneration, diabetes, and heart disease. This symposium will focus on recent ground breaking medical research using stem cells where it has become clear that adult stem cells have outstanding advantages in terms of immediate clinical application, safety and feasibility over all sources of stem cells.

8:30 AM **Registration and Refreshments**

9:00 AM **Welcome Remarks**

→ 9:10 AM **Hematopoietic Stem Cell Transplantation for Autoimmune Diseases**
Richard Burt, M.D., *Northwestern University*

9:50 AM **Autologous Umbilical Cord Blood Transfusion in Children with Type 1 Diabetes**
Michael Haller, M.D., *University of Florida*

10:30 AM **Coffee Break**

10:50 AM **TBA**
Cladd Stevens, M.D., *New York Blood Center*

11:30 AM **Influence of HLA Disparity and Graft Lymphocytes on Allogeneic Engraftment and Survival After UCB Transplant in Adults**
Mary Laughlin, M.D., *Case Western Reserve University*

12:10–1:15 PM Lunch

1:15 PM **A Phase 1 Clinical Study of Human CNS Stem Cells (HUCNS-SC) in Neuronal Ceroid Lipofuscinosis**
Robert Steiner, M.D., *Oregon Health and Science University*

1:55 PM **The Promise of Facilitating Stem Cell Mediated Reversal of Diabetes and Promoting Islet Neogenesis**
Suzanne Ildstad, M.D., *University of Louisville*

2:35 PM **Adipose Stem Cells for Wound Healing: The Therapeutic Impact of Cell Preparation and Delivery**
Adam Katz, M.D., *University of Virginia*